Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Monolithic Power Systems Inc (MPWR) Price & Performance

AbCellera Biologics IncTrade
Monolithic Power Systems IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Monolithic Power Systems Inc — how do they compare? AbCellera Biologics Inc trades at $9.86 (market cap $2.99B), while Monolithic Power Systems Inc trades at $1,448 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 23× AbCellera Biologics Inc's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLMPWR
Market Cap
$2.99B$68.90B
Sector
HealthUtilities
52-Week High
$9.76$1.69K
52-Week Low
$2.78$820.74
Enterprise Value
$2.58B$67.51B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.

The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.

Monolithic Power Systems Inc

MPWR is trading at $1,446.91, up 4.77% in the last 24 hours, with a bullish technical signal and strong earnings momentum after beating Q2 2026 estimates. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, though valuation ratios like P/E of 85.55 are elevated. Recent news highlights AI-driven revenue growth and a legal investigation into potential misleading statements.

The outlook is positive with an 88% analyst buy rating and a $1,870 consensus price target, but risks include high valuation sensitivity, competitive pressures, and legal scrutiny. Earnings growth from AI infrastructure demand remains a key catalyst for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Monolithic Power Systems Inc

Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.

Read more on MPWR